Immunosuppressive Therapy for Transplant Market
Number of pages: 100 | Report Format: PDF | Published date: February 27, 2023
Historical Years – 2020 | Base Year – 2021 | Forecasted Years – 2022-2030
|
Report Attribute |
Details |
|
Market Size Value in 2021 |
US$ 7.54 billion |
|
Revenue Forecast in 2030 |
US$ 10.78 billion |
|
CAGR |
4.56% |
|
Base Year For Estimation |
2021 |
|
Forecast Period |
2022-2030 |
|
Historical Year |
2020 |
|
Segments Covered |
Drug Class, Transplant Type, and Region |
|
Regional Scope |
North America, Europe, Asia Pacific, and the Rest of the World (RoW) |
According to the deep-dive market assessment study by Growth Plus Reports, the global immunosuppressive therapy for transplant market was valued at US$ 7.54 billion in 2021 and is expected to register a revenue CAGR of 4.56% to reach US$ 10.78 billion by 2030.
Immunosuppressive Therapy for Transplant Market Fundamentals
Immunosuppressive therapy is the medication to stifle the body’s immunity to inhibit the ability of transplant rejection. In immunosuppressive therapy, different types of drugs are administered to lower the immune defense mechanism in the body after the transplantation of different organs or stem cells. Anti-rejection immunosuppression refers to the drugs administered to treat an acute rejection event during the first post-transplant phase or during a specified follow-up phase, often lasting up to 30 days after the diagnosis of acute rejection. Post-transplant immunosuppression typically entails a combination of medications and strategies depending on the patient’s circumstances. Possible strategies include different approaches. In induction immunosuppression, all drugs are administered right away after transplantation in heightened doses to prevent acute rejection incorporated. These medications are not used for long-term immunosuppressive maintenance, although they may be continued after discharge for the first 30 days following the transplant. In maintenance immunosuppression, all immunosuppressive drugs administered before, during, or after transplant are maintained over the long term. Prednisone, cyclosporine, tacrolimus, mycophenolate mofetil, azathioprine, or rapamycin are a few examples of drugs used. Additionally, immunosuppressive drugs used for induction or to treat bouts of rejection are not included in maintenance immunosuppression.
[75465646]
Immunosuppressive Therapy for Transplant Market Dynamics
The increase in organ transplant procedures, such as kidney and liver transplants, brought on by a rise in the prevalence of organ damage also contributes to the expansion of immunosuppressive therapy for the transplant market. In the last few decades, the need for organ transplantation has significantly expanded worldwide due to a rise in the prevalence of crucial organ failure, an increase in success rates, and improvements in post-transplant outcomes. Furthermore, the market for immunosuppressive therapy for transplants is expected to rise dramatically over the coming years due to the involvement of prominent market players and the rise in government initiatives. Research and medical institutes and prominent stakeholders worldwide are increasingly focusing on coordinated efforts to offer more effective treatment choices for life-threatening conditions. These collaborative efforts are predicted to stimulate market revenue growth significantly. The market’s development is also fueled by the rising interest in the development and usage of new treatment options with more benefits than traditional ones. Patients are increasing preference to have transplantation surgery in order to avoid medical procedures, such as dialysis, live a longer and less painful life, spend less time in the hospitals, undergo fewer surgeries, or take fewer medications. The high demand for transplantation is the most important driving factor for the global immunosuppressive therapy for transplant market.
However, the high cost of the transplantation process with post-surgical side effects is the major restraining factor for the global immunosuppressive therapy for transplant market. Additionally, the lack of suitable donors is also a crucial reason for hindering market revenue growth potential.
Immunosuppressive Therapy for Transplant Market Ecosystem
The global immunosuppressive therapy for transplant market is analyzed from three perspectives: drug class, transplant type, and region.
Immunosuppressive Therapy for Transplant Market by Drug Class
[7564664]
Based on the drug class, the global immunosuppressive therapy for transplant market is segmented as calcineurin inhibitors, antiproliferative agents, antibodies, small biological agents, and others.
The calcineurin inhibitor segment accounted for the largest revenue share of the global immunosuppressive therapy for transplant market in 2021. Calcineurin inhibitors are drugs that stop calcineurin from functioning. The enzyme calcineurin activates the immune system’s T-cells. White blood cells, known as T-cells (T-lymphocytes), are essential for cell-mediated immunity. Given its effectiveness and long usage history in kidney transplant patients, calcineurin inhibitors are the most frequently used immunosuppressive therapy. The two drugs that comprise this therapeutic class, tacrolimus (TAC) and cyclosporine A (CSA), have been administered to kidney transplant recipients for over 20 years. Thus, the primary driving factors in the calcineurin inhibitors segment growth include the increasing prevalence of kidney failures and liver damage, which is anticipated to boost the demand for kidney and liver transplantation, and technical developments in organ transplantation.
Immunosuppressive Therapy for Transplant Market by Transplant Type
Based on the treatment type, the global immunosuppressive therapy for transplant market is segmented as organ transplant and stem cells (blood/bone marrow) transplant.
The organ transplant segment accounted for the largest revenue share in the market in 2021. Growing awareness about organ transplantation procedures is spurring the development of the organ transplant segment. Government and industrial involvement in promoting organ transplant awareness significantly impact the global market. The number of organ donors has also increased due to the rising awareness. It has led to a high acceptance rate in patients for transplantation, supporting the growth of the immunosuppressive therapy for transplant market. Furthermore, the rising incidence of organ failure also fuels the demand for organ care, increasing the need for immunosuppressive drugs. Kidney transplantation is the most predominant organ transplant segment influencing the revenue growth of the global immunosuppressive therapy for transplant market, owing to the rising prevalence of kidney diseases and the adoption of better diagnostic tools.
Immunosuppressive Therapy for Transplant Market by Region
Based on the region, the global immunosuppressive therapy for transplant market is segmented into North America, Europe, Asia Pacific, and the Rest of the World.
North America accounted for the largest revenue share of the global immunosuppressive therapy for transplant market in 2021. The rising incidence of chronic diseases leading to organ failures can be attributed to the market’s revenue growth. A significant portion of the regional market’s expansion is also driven by rising healthcare spending, tissue engineering and organ transplantation technology developments, and well-established healthcare infrastructure.
The market in Asia Pacific is anticipated to grow at the highest revenue CAGR during the forecast period, due to the increase in public awareness about organ donation. Additionally, rising healthcare costs, improving disposable incomes, and growing government initiatives to make immunosuppressant medications accessible to patients contribute to the market’s rapid expansion in the region.
Immunosuppressive Therapy for Transplant Market Competitive Landscape
The leading companies in the global immunosuppressive therapy for transplant market are:
Immunosuppressive Therapy for Transplant Market Strategic Developments
Immunosuppressive therapy refers to the drugs administered to treat an acute rejection event during the first post-transplant phase or during a specified follow-up phase, often lasting up to 30 days after the diagnosis of acute rejection.
The rising prevalence of chronic diseases and increasing awareness regarding transplantation are the most important drivers of the global immunosuppressive therapy for transplant market.
Astellas Pharma Inc., Accord Healthcare Ltd., AbbVie, Inc., Novartis AG, and Genzyme Corporation (Sanofi S.A.) are among the top market players.
The high cost of treatment, organ failure, and stringent regulations for organ donation are likely to hinder the development of the global immunosuppressive therapy for transplantation market.
The global immunosuppressive therapy for transplant market is expected to register a revenue CAGR of 4.56% during the forecast period from 2020 to 2030.
*Insights on financial performance are subject to the availability of information in the public domain